A Combination Therapy Including Anti-PD-1 Immunotherapy in Rectal Cancer With Refractory Distal Metastasis

NCT05359406 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

51

Enrollment

OTHER

Sponsor class

Conditions

Advanced Rectal Cancer
Distal Metastasis

Interventions

COMBINATION_PRODUCT: a combination therapy including tislelizumab

Sponsor

LI XIN-XIANG